Travere Therapeutics (TVTX)
(Delayed Data from NSDQ)
$7.42 USD
+0.40 (5.70%)
Updated May 31, 2024 04:00 PM ET
After-Market: $7.42 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth F Momentum F VGM
Brokerage Reports
Travere Therapeutics, Inc. [TVTX]
Reports for Purchase
Showing records 121 - 130 ( 130 total )
Company: Travere Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Travere Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Delving More Into DUPLEX - Raising Target to $46 on TVTX
Provider: WEDBUSH SECURITIES INC.
Analyst: CHICO L
Company: Travere Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Travere Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
With Most Of The Fireworks Already Shot Off, Looking For Quiet 4Q20 Reporting
Provider: WEDBUSH SECURITIES INC.
Analyst: CHICO L
Company: Travere Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Travere Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Glomerular Disorders 101: A Deep Dive Primer On Glomerular Dysfunction
Provider: WEDBUSH SECURITIES INC.
Analyst: CHICO L
Company: Travere Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Travere Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Looking For More Than Love In The Air In February - DUPLEX Data Feb 2021
Provider: WEDBUSH SECURITIES INC.
Analyst: CHICO L
Company: Travere Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Travere Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
A Wrap On DUPLEX Enrollment; On To The Readout For Sparsentan and TVTX
Provider: WEDBUSH SECURITIES INC.
Analyst: CHICO L